NexP™ protein carrier is derived from A1AT (alpha-1 antitrypsin), which is abundant in human blood and has been used for many year and proved for safety.
Therapeutic proteins or peptides fused with NexP™ show excellent properties as long-acting therapeutic proteins and peptides without causing any loss of activity as medicines.
In pharmacokinetics and pharmacodynamics studies using mice/rats and monkey,
the experimental drugs through NexP™fusion technology demonstrated the increased in-vivo half life and improved potency which serve the promising features of less frequent dosing, less side effects and better clinical efficacy.
NexP™ can be fused at both C-terminus and N-terminus of proteins and peptides,
this NexP™ fusion technology is a platform technology for next generation long-acting therapeutics.